Prostate Cancer: Overdiagnosis in Solid Organ Transplant Recipients
Overall incidence of prostate cancer decreased between 2003 and 2017.
Urology News
UROLOGY NEWS
Tool Could Optimize Antibiotic Prescribing for UTI
Researchers tested a new decision support tool to optimize antibiotic prescribing for uncomplicated urinary tract infection.
Phase 3 Trial in RCC: Atezolizumab Plus Cabozantinib After Progression With ICIs
A phase 3 randomized active-controlled trial will evaluate atezolizumab plus cabozantinib among patients with advanced RCC whose disease progressed with ICIs.
Low, But Increasing, Use of Palliative Care Seen in RCC
Patients who were Black, had higher incomes, or who had undergone surgery were less likely to receive palliative care.
Phase 3 Trial Planned for Cabozantinib Plus Nivolumab-Ipilimumab in RCC
A double-blind, placebo-controlled phase 3 trial is planned to evaluate cabozantinib plus nivolumab and ipilimumab as first-line treatment for advanced clear cell RCC..
Phase 3 Study to Evaluate HIF-2α Inhibitor in RCC
A phase 3, randomized, active-controlled trial will evaluate the efficacy and safety of a HIF-2α inhibitor for the second-line treatment of clear cell RCC.
Modified Nivolumab-Ipilimumab Dosing Shows No Benefit in Advanced RCC
A modified dosing regimen of nivolumab-ipilimumab for patients with advanced RCC did not provide additional benefit compared with standard dosing.
Phase 2 Study Initiated for HIF-2α Agent in Relapsed/Refractory RCC
A phase 2 trial has been initiated to evaluate a HIF-2α inhibitor for the treatment of advanced RCC after progression with another therapy.
Phase 3 Trial of Nivolumab With or Without Ipilimumab for Localized RCC After Nephrectomy
A phase 3 randomized placebo-controlled trial is recruiting to evaluate nivolumab plus ipilimumab among patients with localized RCC at risk of relapse after nephrectomy.
No Benefit to Modified Dosing of Lenvatinib-Everolimus in Advanced RCC
Modified dosing of lenvatinib-everolimus did not improve tolerability and may have modestly decreased efficacy compared with standard dosing in advanced RCC.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Overactive Bladder (OAB)
